|
Jun 30
|
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
|
|
Jun 30
|
Will CVS Health's Formulary Move Boost Its Weight Management Program? (Revised)
|
|
Jun 30
|
Hardman Johnston Global Equity Sold Novo Nordisk (NVO) due to Weak Script Trends
|
|
Jun 29
|
This Dirt Cheap Healthcare Stock Could Be a Hidden Artificial Intelligence (AI) Opportunity (Hint: It's Not Eli Lilly)
|
|
Jun 28
|
Hims & Hers (HIMS) Jumps 6.76% Anew as Investors Cheer Weight Loss Drug Fight
|
|
Jun 28
|
Hims & Hers' ugly split with Wegovy maker weighs on the telehealth company's future
|
|
Jun 28
|
Novo Nordisk (NVO) Terminates Hims & Hers Partnership Over Wegovy Sales Issues
|
|
Jun 28
|
Citi Expresses Optimism for Eli Lilly and Company (LLY)
|
|
Jun 27
|
Hims & Hers (HIMS) Rallies 11.76% as CEO Not Backing Down After Novo Nordisk Spat
|
|
Jun 27
|
Is It Too Late to Buy NVIDIA?
|
|
Jun 27
|
Novo Nordisk announces WeightWatchers collaboration for Wegovy
|
|
Jun 27
|
NVO vs. LLY: Which Obesity Powerhouse is the Stronger Bet Now?
|
|
Jun 27
|
Amgen Looks to Take Share of Booming Obesity Space: Will It Succeed?
|
|
Jun 27
|
AbbVie Adds More Than $24B in 6 Months: How to Play ABBV Stock
|
|
Jun 27
|
Novo Nordisk teams up with WeightWatchers in latest telehealth push
|
|
Jun 27
|
Weekly Recap: 12 Health Press Releases You Need to See
|
|
Jun 27
|
Hims & Hers Stock Tumbles as Novo Nordisk Ends Its Wegovy Sales Deal. Can the Telehealth Giant Recover?
|
|
Jun 27
|
Novo Nordisk says WeightWatchers will sell Wegovy
|
|
Jun 26
|
Sector Update: Health Care Stocks Edge Higher Late Afternoon
|
|
Jun 26
|
Why Is Hims & Hers Health (HIMS) Stock Soaring Today
|